Big pharma and investors re-engage in CGTs and race to scale
To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.
Healthcare
Investors bet on newer technology and indications for CGTs
Redefining clinical trials in oncology and rare diseases across the Europe
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle
FDA halts uniQure’s plans for Huntington’s disease gene therapy
Sensei to ditch its lead candidate and cut workforce amidst strategic review
FDA gives first approval for recurrent respiratory papillomatosis therapy
Sartorius to invest $3m for minority share in biotech start-up Nanotein
